Atrás
Precio Salarius Pharmaceuticals, Inc. (SLRX)
Gráfico del Precio de Acciones SLRX
SLRX Ganando
Salarius Pharmaceuticals, Inc.
$0.78
3.93%
$0.02
Al cierre: Jan 23, 16:00:00 GMT-5
$0.78
0%
$0
Mercado Posterior: Jan 23, 20:00:00 GMT-5
Sin datos aúnEarnings FAQ
¿Cómo se comparó el EPS reciente de SLRX con las expectativas?
¿Cómo fue el desempeño de los ingresos de Salarius Pharmaceuticals, Inc. SLRX en el último trimestre?
¿Cuál es la estimación de ingresos para Salarius Pharmaceuticals, Inc.?
¿Cuál es la puntuación de calidad de ganancias de Salarius Pharmaceuticals, Inc.?
¿Cuándo informa Salarius Pharmaceuticals, Inc. sus ganancias?
¿Cuáles son las ganancias esperadas de Salarius Pharmaceuticals, Inc.?
¿Superó Salarius Pharmaceuticals, Inc. las expectativas de ganancias?
Estadísticas clave
Cierre Anterior
$0.7505
Precio de apertura
$0.7948
Rango del día
$0.77 - $0.84
Rango de 52 semanas
$0.5148 - $44.1
Volumen
--
Volumen promedio
3.6M
EPS (TTM)
-24.24
Rendimiento de dividendos
--
Cap. de mercado
$4.5M
¿Qué es Salarius Pharmaceuticals, Inc.?
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2015-01-29. The firm is focused on advancing its pipeline of peptide conjugate therapeutics engineered through its IMP3ACT platform that reduces the complexity of drug development and manufacturing. The company is focused on developing effective treatments for patients with cancer with high, unmet medical needs. The company’s lead candidate, seclidemstat (SP-2577), is being studied as treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options. Its pipeline consists of SP-3164 a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. SP-3164 is a next-generation cereblon-binding MG. SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold.
Características
Estrategias de Trading
© 2025 Finture Development Limited. All rights reserved